Contribute Try STAT+ Today

As controversy rises over equal access to Covid-19 medical products, a manufacturer of rapid, point-of care tests is being urged to lower the price of its diagnostic and also increase sales to a World Health Organization diagnostics consortium designed to serve low-income countries.

At issue is a test developed by Cepheid, which charges $19.80 for the test for 145 developing countries represented by the consortium. Doctors Without Borders argues the company could still make a profit if the price was lowered to $5. The relief organization extrapolated data from an analysis of a Cepheid test for tuberculosis, which found expenses amounted to $3 in production cost, at high sales volumes.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.